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Abstract
Background: HIV protease (PR) is a virus-encoded aspartic protease that is essential for viral replication and
infectivity. The fully active and mature dimeric protease is released from the Gag-Pol polyprotein as a result of
precursor autoprocessing.
Results: We here describe a simple model system to directly examine HIV protease autoprocessing in transfected
mammalian cells. A fusion precursor was engineered encoding GST fused to a well-characterized miniprecursor,
consisting of the mature protease along with its upstream transframe region (TFR), and small peptide epitopes to
facilitate detection of the precursor substrate and autoprocessing products. In HEK 293T cells, the resulting chimeric
precursor undergoes effective autoprocessing, producing mature protease that is rapidly degraded likely via
autoproteolysis. The known protease inhibitors Darunavir and Indinavir suppressed both precursor autoprocessing
and autoproteolysis in a dose-dependent manner. Protease mutations that inhibit Gag processing as characterized
using proviruses also reduced autoprocessing efficiency when they were introduced to the fusion precursor.
Interestingly, autoprocessing of the fusion precursor requires neither the full proteolytic activity nor the majority of
the N-terminal TFR region.
Conclusions: We suggest that the fusion precursors provide a useful system to study protease autoprocessing in
mammalian cells, and may be further developed for screening of new drugs targeting HIV protease
autoprocessing.
Background
Human immunodeficiency virus 1 (HIV-1) is the causa-
tive pathogen of AIDS. The HIV protease is a virus-
encoded enzyme absolutely required for virus propaga-
tion and infectivity. In the HIV infected cell, unspliced
genomic RNA serves as mRNA for the synthesis of Gag
and Gag-Pol polyproteins [1,2]. As part of the Gag-Pol
polyprotein, the HIV protease is flanked at the N-termi-
nus by a transframe region (TFR) and at the C-terminus
by the reverse transcriptase [3,4]. The embedded pro-
tease has intrinsic but limited proteolytic activity [5,6]
and the full activity is associated with the mature pro-
tease following its liberation from the precursor. Pro-
duction of mature protease appears to be catalyzed by
the Gag-Pol precursor itself serving as both the
substrate and enzyme, thus the process is defined as
protease autoprocessing [3] although it remains unclear
whether the initial cleavage is intra- or inter-molecular
[7,8]. The mature protease contains 99 amino acid resi-
dues and is a member of the aspartyl protease family
[3,4,9]. It exists as stable homodimers (Kd < 5 nM) and
the catalytic site is formed at the dimer interface by two
aspartic acids, one from each monomer, that are
required for proteolytic activity. Alteration of D25 to
either asparagine or alanine abolish protease activity in
vitro and in vivo [3,10-12]. Because of the requirement
for two aspartate residues that are at the dimer inter-
f a c e ,i ti sb e l i e v e dt h a tp r o t e a s ep r e c u r s o rd i m e r i z a t i o n
is essential for formation of the catalytic site to initiate
protease autoprocessing [3].
HIV protease cleaves multiple sites in the Gag and
Gag-Pol polyproteins [3]. The cleavage efficiency at each
recognition site varies likely due to the diversity of
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the MA/CA and the p2/NC sites, can be cleaved by
both precursor and mature proteases [6,13], and pep-
tides containing these sites have been used as standard
substrates for examination of protease activity in vitro.
In contrast, other recognition sites require the fully
active mature protease. For example, cleavage of p25
(CA-p2) at the CA/p2 site, which releases p24 (CA), has
been shown to require the fully active mature protease.
In fact, the amount of p24 (CA) relative to p25 (CA-p2)
and other p24-containing proteins such as the full
length Gag polyprotein in the released virions, i.e.G a g
processing efficiency, has been used as an indirect mea-
surement to reflect mature protease activity and/or pro-
tease autoprocessing efficiency [14]. Effective cleavage of
all these sites following a defined sequence is essential
for the production of infectious progeny virions. Muta-
tions that alter the time of processing, the order in
which the sites are cleaved, or that produce an incorrect
cleavage at any individual site, cause the release of aber-
rant virions that are significantly less infectious [15-18].
Because HIV protease plays a critical role in viral infec-
tivity, protease inhibitors targeting the catalytic site have
been routinely used in combination with inhibitors tar-
geting other viral components in antiretroviral therapy
(ART).
In contrast to the well known function of the HIV
protease, the molecular and cellular mechanisms med-
iating precursor autoprocessing remains largely illusive.
Between the two cleavage sites that lead to liberation of
the mature protease, the C-terminal cleavage seems to
have less of an impact on the regulation of autoproces-
sing as mutations blocking this cleavage have no signifi-
cant influence on protease activity or Gag processing in
transfected mammalian cells [19,20]. In contrast, muta-
tions blocking N-terminal cleavage abolish Gag proces-
sing and lead to loss of viral infectivity [21,22],
suggesting that N-terminal cleavage plays an important
role in regulating autoprocessing. Consistent with this, a
miniprecursor comprised of a slightly modified mature
protease plus the upstream TFR has been utilized as a
model system to study protease autoprocessing [3,23].
When expressed in E. coli, the miniprecursor is predo-
minantly associated with inclusion bodies and is there-
fore purified under denaturing conditions and refolded
in vitro. Structural and functional analyses of the result-
ing miniprecursor have demonstrated that cleavage at
the N-terminus of the protease is concomitant with the
formation of a stable dimer and the appearance of cata-
lytic activity [3]. Another approach to assess autoproces-
sing is to use proviruses that carry various protease
mutations; however, it has been difficult to directly
detect autoprocessing intermediates associated with
transfected or infected cells. Because of this limitation,
proteolytic cleavage of the Gag polyprotein has been
measured as an indirect readout of autoprocessing effi-
ciency and/or protease activity.
In order to further define viral and/or cellular deter-
minants that regulate HIV protease autoprocessing, we
recently reported a GST-miniprecursor fusion that
undergoes autoprocessing in E. coli [24]. GST was cho-
sen as a fusion tag to increase protein solubility and
facilitate precursor dimerization. The reported GST-
TFR-PR contains two natural cleavage sites: one at the
N-terminus of TFR (referred to as the distal site) and
the other between TFR and PR (the proximal site). In
the present study, a similar fusion construct was engi-
neered for mammalian expression to examine protease
autoprocessing in transfected mammalian cells. Autop-
rocessing of the fusion precursors carrying protease
mutations that were previously characterized with pro-
virus constructs was examined to evaluate utility of the
system. We demonstrate that the GST-miniprecursor
fusions mirror phenotypes described in other model sys-
tems and therefore provide a simple system for further
analysis of protease autoprocessing.
Results
GST fused protease miniprecursors undergo
autoprocessing in E. coli and HEK293T cells
We previously reported that a miniprecursor fusion
(GST-TFR-PR
pse-Flag) exhibited autoprocessing in
E. coli, and we were able to isolate Flag-tagged mature
protease from whole cell lysates using anti-Flag anti-
body [24]. Here, we demonstrate that the mature pro-
tease is the predominant product in E. coli whole cell
lysates as detected with either anti-Flag or anti-PR
antibody (Figure 1A lane 3). It is unlikely that the clea-
vage reactions were catalyzed by a cellular protease
because catalytic site mutation (D25N) ablated autop-
rocessing resulting in the full-length fusion precursor
as the major band (Figure 1A lane 2). We also
observed two bands that are smaller than the full
length fusion precursor in the D25N mutant. The fact
that both fragments were reactive to anti-PR and anti-
Flag suggested that they were likely produced as a
result of proteolytic cleavage in the GST domain.
These cleavages appear characteristic with fusion pre-
cursors with inactive (D25N) or reduced (H69E) pro-
tease activities as reported previously [24], but are
beyond the expected cleavage sites essential for pro-
tease autoprocessing. We did not pursue this further
as it seems unrelated to protease autoprocessing
We next constructed a mammalian expression plasmid
to evaluate autoprocessing of GST-miniprecursor fusion
in mammalian cells. The rabbit anti-PR used for pro-
tease detection in E. coli lysates failed to distinguish
positive signal from background noise in 293T lysates
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intermediates, we engineered the expression plasmid to
have a Flag tag between the GST and the TFR, and a
HA tag at the C-terminus of the protease. The resulting
fusion precursor (GST-Flag-TFR-PR
pse-HA) exhibited
effective autoprocessing in transfected HEK 293T cells
as indicated by the disappearance of the full length
precursor and appearance of a processing product
(GST-Flag-TFR) (Figure 1B lane 3). Like in E. coli,
autoprocessing was dependent on active HIV protease
because the mutant precursor (D25N) with a deficient
catalytic site exhibited little or no autoprocessing (Figure
1B lane 2). Unlike in E. coli,w h e r et h em a t u r ep r o t e a s e
is detectable, the HA-tagged mature protease was not
detected by the HA antibody even though the antibody
successfully identified the full-length precursor. We
interpreted that the mature protease was rapidly
degraded in transfected mammalian cells as a result of
autoproteolysis that is characteristic of HIV PR [25].
Interestingly, only the proximal site of the pseudo wild-
type protease miniprecursor was cleaved, releasing GST-
Flag-TFR; no GST-Flag was produced suggesting the
distal site was not cleaved. Nevertheless, our data
demonstrated that the GST-miniprecursor fusions are
competent for autoprocessing in mammalian cells.
Darunavir and Indinavir inhibit fusion precursor
autoprocessing in transfected 293T cells
To further examine autoprocessing specificity, we next
tested whether known HIV protease inhibitors suppress
autoprocessing. In the absence of inhibitors, the pseudo
wild type precursor fusion effectively underwent autop-
rocessing; almost no full-length precursor was detected
(Figure 2 lane 3). In contrast, the D25N mutant demon-
strated the full length precursor as the major product
that was detected by both anti-Flag and anti-HA antibo-
dies. In the presence of cell-permeable Darunavir and
Indinavir [26,27], precursor autoprocessing was inhibited
in a dose-dependent manner, as indicated by the appear-
ance of increasing amounts of full length precursor. In
addition, HA-tagged mature protease became detectable
in the presence of low concentrations of protease inhibi-
tor. This data suggested that reduced protease activity
hindered degradation of the mature protease whereas
Figure 1 Autoprocessing of GST- miniprecursor fusions in E. coli and HEK 293T cells. A Bacteria E. coli BL21(DE3) bearing pGEX-3X derived
plasmids encoding the indicated miniprecursor construct were induced with 40 μM of IPTG to express fusion proteins. Total cell lysates were
subjected to 12% SDS-PAGE and western blotting using monoclonal mouse anti-Flag and polyclonal rabbit anti-PR primary antibodies and IR700
goat anti-mouse and IR800 goat anti-rabbit secondary antibodies. Images of both channels are presented. Samples were run on the same gel
but lanes were re-arranged for presentation. Schematic diagrams of the full-length fusion precursor and processing products are indicated at left.
B. HEK293T cells were transfected with pEBG-derived plasmids expressing the indicated fusion protein using the calcium phosphate method.
Post-nuclear cell lysates were prepared at 40 h post-transfection and analyzed by 12% SDS-PAGE and western blotting. Aliquots (~ 20 μL) of
each sample were examined in parallel with either monoclonal mouse anti-Flag or anti-HA primary antibody and IR800 goat anti-mouse
secondary antibody. Molecular mass markers (kDa) are indicated at right.
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degradation.
We also examined inhibitor effects on NL4-3-derived
proviral constructs for comparison with the GST fusion
miniprecursor system (Figure 2B). A mouse monoclonal
p24 antibody was used to detect p24 and other p24-
containing proteins such as p55. Steady-state levels of
the full-length Gag polyprotein (p55) in transfected cells
were very similar in the presence or absence of inhibi-
tors (Figure 2B, bottom two panels). The amounts of
p24 in virus-like particles (VLPs) released into the cul-
ture medium were examined as an indirect measure-
ment of protease activity and/or autoprocessing
efficiency[14]. The top panel of Figure 2B demonstrated
that p24 protein was easily detectable in VLPs produced
by the pseudo wild-type HIV protease construct (Figure
2B lane 13), whereas VLPs produced by the D25N
mutant contained only the full length Gag (Figure 2B
lane 12). In the presence of protease inhibitors, Gag
processing was impeded in a dose-dependent manner.
At low concentrations of inhibitors, Gag polyprotein
was partially processed as indicated by the presence of
some processing intermediates (Figure 2B lanes 14 &
17). It should be noted, however, that very little or no
p24 was detected even at low concentrations of inhibi-
tor, confirming that p24 production strictly requires the
fully active mature protease. In the presence of high
concentrations of inhibitors, the full length Gag poly-
protein became the predominant product in the
released VLPs, indicating a complete lack of protease
activity. Our data indicated that Gag processing in VLP
qualitatively correlated with autoprocessing of the GST-
fused precursors in transfected mammalian cells. Partial
inhibition of protease activity completely prevented pro-
duction of p24, but only partially blocked the autopro-
cessing of the GST-fusion precursors.
Autoprocessing of mutant fusion precursors in
transfected 293T cells
We next constructed precursor fusions carrying pre-
viously characterized mutations to examine whether the
precursor fusions would reproduce previous observa-
tions in transfected 293T cells. First, H69 mutations in
the context of either the pseudo wild type (PR
pse)o rt h e
NL4-3-derived (PR
NL) protease backbone were analyzed
(Figure 3, left). H69 is a surface residue on the mature
protease, but we recently reported that alterations of
H69 modulate precursor structures and thus influence
protease autoprocessing and the subsequent Gag proces-
sing [14,24]. For example, PR
pse H69E was defective for
Gag processing in VLPs produced from cells that were
transfected with PR
pse H69E proviral DNA, whereas
H69Q had minimal impact [24]. Here, we also found
reduced autoprocessing in cells transfected with the
Figure 2 Known protease inhibitors block protease autoprocessing. A. HEK293T cells transfected with the indicated pEBG construct were
incubated with or without protease inhibitors at increasing concentrations. Darunavir: 0.1 μM, 1 μM and 10 μM; Indinavir: 1 μM, 10 μM and 100
μM. Post-nuclear cell lysates were prepared at 40 h post-transfection and aliquots (~20 μL) of each sample were analyzed in parallel using
monoclonal mouse anti-Flag, anti-HA, anti-GAPDH primary antibodies and IR800 goat anti-mouse secondary antibody. Schematic diagrams of the
full length fusion precursor and processing products are indicated at left. Molecular mass markers (kDa) are indicated at right. B. HEK293T cells
that were transfected with NL4-3-derived proviruses encoding the indicated proteases were incubated with or without protease inhibitors at the
same concentrations as in panel A. Post-nuclear cell lysates (Cell) and VLP particles (VLP) were prepared as described (Materials and Methods)
and subjected to western blot analysis using monoclonal mouse anti-p24. The full length Gag polyprotein (p55) and p24/p25 doublet are
indicated at left.
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pse H69E fusion precursor as indicated by the accu-
mulation of the full-length precursor compared to the
wild type (PR
pse) and H69Q controls (Figure 3 lane 7-9).
In addition, the wild type PR
pse mature protease was
undetectable but HA-tagged mature H69E protease was
identified in the cell lysate. Because the H69E pseudo
wild type protease has reduced proteolytic activity [24],
this indicated once again that inhibition of protease
activity slows down protease degradation, consistent
with the detection of mature protease in the presence of
inhibitors.
Using provirus as a test model we recently demon-
strated that H69 mutations in the context of the pseudo
wild type (PR
pse) or NL4-3-derived (PR
NL) proteases
exert different effects on protease autoprocessing and
subsequent Gag processing efficiency. For example,
H69E mutation abolished Gag processing in the PR
pse
backbone, but only showed mild reduction in Gag pro-
cessing in the PR
NL backbone; the PR
NL H69D displayed
a Gag processing phenotype similar to PR
pse H69E [14].
With the mammalian GST fusion expression system, we
observed similar results, as indicated by the amount of
full length precursor remaining in the lysate (Figure 3,
left panel). Furthermore, HA-tagged mature proteases
containing mutations that significantly reduced Gag pro-
cessing in the proviral system were also detected in the
mammalian expression system (Figure 3, bottom, lanes
3 and 7), suggesting a contribution of reduced protease
activity to Gag processing deficiency. There are six
point mutations of amino acid between PR
pse and PR
NL.
We recently reported that the inhibitory effect of PR
pse
H69E mutation on Gag processing efficiency is ham-
pered when the same mutation is placed into the PR
NL
backbone and C95 is the primary contributing residue
out of the six variations between PR
pse and PR
NL [14].
Using the GST fusion precursors, we also observed that
PR
NL H69E had higher protease activity than PR
pse
H69E as indicated by reduced amount of the full-length
precursor and no detection of HA-tagged mature pro-
tease (Figure 3 lane 4 vs lane 7). PR
pse H69E/A95C
mutation showed autoprocessing activity similar to PR
NL
H69E (lane 12 vs lane 15), consistent with the previous
report that C95 residue suppressed the inhibitory effect
of H69E in the pseudo wild type backbone. Collectively,
our data suggest that mutant phenotypes obtained
with other model systems are reproducible with the
Figure 3 Differential effects of H69 mutations on protease autoprocessing. pEBG-derived plasmids expressing the indicated fusion proteins
were transfected into HEK293T cells using calcium phosphate and post-nuclear cell lysates were prepared at 40 h post transfection. Aliquots
(~20 μL) of each sample were subjected to western blotting in parallel using monoclonal mouse anti-Flag or anti-HA primary antibodies and
IR800 goat anti-mouse second antibody. The full-length fusion precursor and processing products are indicated in the middle; molecular mass
markers (kDa) are indicated at left.
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and that reduced Gag processing qualitatively correlates
with reduced protease activity.
The anti-Flag antibody revealed additional information
of protease autoprocessing. We observed moderate
amounts of autoprocessing products, such as GST-Flag
and GST-Flag-TFR, in all cell lysates except for the
D25N negative control, suggesting autoprocessing
occurred even with the mutant proteases such as PR
NL
H69D and PR
pse H69E. Another interesting observation
was differential recognition of the proximal and distal
cleavage sites. The pseudo wild type protease preferen-
tially cut at the proximal site, directly releasing the
mature protease as the only product, whereas the NL4-
3-derived protease cut both sites, with a slight prefer-
ence to the distal site (Figure 3 lane 6). Alteration of
H69 in the PR
pse backbone also changed cleavage prefer-
ence, resulting release of two GST-containing processing
products in PR
pse H69 mutants.
To further study autoprocessing dynamics, we exam-
ined steady state levels of protease autoprocessing pro-
ducts at different time points (Figure 4). At 24, 35 and
51 hours post-transfection, the overall distribution pat-
tern of precursor and cleavage products was very similar
to that observed at 40 h post-transfection (Figure 3). For
active proteases (wt and H69Q), neither the full length
precursor nor mature protease was detectable at any
time point examined. This suggested a rapid disappear-
ance of both the precursor substrate and the mature
protease product over the time course that was exam-
ined. The other two autoprocessing products, GST-Flag-
TFR and GST-Flag, demonstrated a slight accumulation
over time, indicating that they are more stable than the
mature protease. The inactiveD 2 5 Np r o t e a s ea l s od i s -
played a slight accumulation of the full-length precursor
over time. For mutant proteases H69E and H69D, accu-
mulation of HA-tagged mature protease was minimal
and transient at 35 h post-transfection and diminished
at 51 h post-transfection, indicating that degradation of
these mutant proteases was slower, but was eventually
complete when production of the precursor decreased
over time. Our data indicated that protease autoproces-
sing occurs rapidly after synthesis of the fusion precur-
sor and that degradation of the mature protease is
proportionally correlated with its activity in this system.
Autoprocessing of GST fusion precursors does not require
TFR
Recently, Leiherer et al reported that the TFR region is
dispensable after it is uncoupled from the p6 coding
sequence in a NL4-3-derived proviral context. For com-
parison, we here sought to examine TFR function in the
context of the GST fusion precursors to further evaluate
the system. A series of N-terminal TFR truncations in
the context of GST-TFR-PR
NL-HA backbone were con-
structed; the shortest TFR mutant only has eight resi-
dues upstream of the proximal cleavage site (Figure 5A).
Interestingly, all of the TFR truncation precursors were
Figure 4 Temporal analysis of protease autoprocessing. pEBG-derived plasmids expressing the indicated fusion precursors were transfected
into HEK293T cells using calcium phosphate. Post-nuclear cell lysates were prepared at the indicated times post transfection and subjected to
western blot analysis using polyclonal rabbit anti-GST (top) and mouse anti-HA (middle) primary antibodies, and IR800 goat anti-rabbit and IR700
goat anti-mouse secondary antibodies. The same blot was stripped and analyzed using mouse anti-GAPDH (bottom) as a loading control. The
full length fusion precursor and processing products are indicated at left; molecular mass markers (kDa) are indicated at right.
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detected. For the wild type precursor, the distal cleavage
was more favourable. However, in the absence of the
distal cleavage site, as in the N-terminal truncations,
effective autoprocessing was also observed, indicating
flexibility of cleavage site usage during autoprocessing.
We also constructed a mutant in which the TFR was
replaced with an unrelated peptide (N-Hec1; 66 residues
derived from the N-terminus of the Hec1 protein) while
keeping the last four residues upstream of the proximal
cleavage site. The resulting fusion precursor also autop-
rocessed as efficiently as the wild type control (Figure
5B lanes 3 & 4). Collectively, our data demonstrated
that the majority of the TFR was dispensable for autop-
rocessing of fusion precursor in transfected mammalian
cells.
Conclusions and Discussion
It has long been believed that HIV protease autoproces-
sing is a highly regulated reaction concomitant with vir-
ion release. However, the detailed molecular and cellular
mechanisms of autoprocessing regulation remain poorly
understood. This is partially attributed to lack of appro-
priate model systems for the study. Most HIV protease
studies have been structure based - there are about four
hundred protease structures reported in the literature.
Almost all crystallized structures are for the dimeric
mature protease, the final product of autoprocessing. In
contrast, no structural information for the protease pre-
cursor is available except for a single monomer protease
structure that has been reported using NMR analysis
of a modified pseudo wild type protease containing a
four-residue extension from the N-terminus and a four-
residue deletion of the C-terminus [8,23]. Structural
analyses of mature protease dimers alone cannot fully
explain the autoprocessing mechanism or reveal the
cause of drug resistance. Proviral DNA mutagenesis on
the other hand has provided insightful information
regarding protease autoprocessing mechanism
[14,19-22,24,28], however, sensitive and direct detection
of the mature protease, along with its precursor and
processing intermediates, has been restrained due to
lack of highly specific and sensitive antibodies. Conse-
quently, most information is indirectly derived from
analysis of Gag processing efficiency and/or p24 produc-
tion [14,24]. We here report a simple model system to
examine protease autoprocessing in transfected mamma-
lian cells, which allows detection of some processing
products at the steady state in the cell lysate. Impor-
tantly, this system was able to reproduce previously
reported phenotypes that were described using mutant
provirus constructs, further validating its utility for
autoprocessing analysis. Autoprocessing of the GST
fusion precursors was also sensitive to protease inhibi-
tors; this cell based system may be further developed for
screening new drugs that inhibit HIV protease
autoprocessing.
The GST fusion precursors also revealed some inter-
esting properties of protease autoprocessing. First of all,
fully active mature proteases were not detectable in the
cell lysates, whereas some mutant proteases such as
PR
pse H69E and PR
NL H69D with reduced activities
were detected. We interpreted this to indicate that the
fully active protease is rapidly degraded in transfected
Figure 5 The TFR is dispensable for autoprocessing of the fusion precursors. A. Schematic diagram depicting truncation and replacement
(N-Hec1) of TRF amino acid sequences in the GST-Flag-TFR-PR
NL precursor. B. Autoprocessing of the resulting fusion precursors in transfected
HEK293T cells. Post-nuclear cell lysates were prepared at 40 h post transfection and subjected to western blotting using monoclonal mouse anti-
Flag or anti-HA primary antibodies and IR800 goat anti-mouse second antibody. Schematic diagrams of the full length fusion precursor and
processing products are indicated at left. Molecular mass markers (kDa) are indicated at right.
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years ago [25]. Given that the mature protease recog-
nizes a wide variety of substrate sequences, autoproteo-
lysis of the mature protease might be advantageous to
the virus once the protease has completed processing of
Gag and Gag-Pol in the virion. With our mammalian
expression system, the degradation efficiency was posi-
tively correlated with protease activity at steady state
levels; more mature protease was detected when pro-
tease activity was decreased. Detection of the mature
form of wild type protease in the presence of protease
inhibitors is consistent with this speculation. However,
it remains to be defined whether additional mechanisms
in mammalian cells are also attributed to the disappear-
ance of fully active mature protease. It is worth noting
that the mature pseudo wild type protease is engineered
to be proteolysis resistant and is readily detectable in
E. coli lysate. However, both the pseudo wild type and
the NL4-3 derived wild type mature proteases are unde-
tectable in transfected HEK293T cells. It is known that
the concentration of PR plays a role in its autoproteoly-
sis, so one possible explanation is that the steady state
PR concentration in E. coli is different from that in
mammalian cells, which remains to be determined.
Curiously, the present study also demonstrated that
autoprocessing of the GST fusion precursor did not
require fully active protease. Except for the D25N
negative control, all the mutant fusion precursors
demonstrated detection of the products generated fol-
lowing cleavage of the distal or proximal sites, respec-
tively, in the cell lysates. Among them, PR
pse H69E is
known to have reduced catalytic activity in vitro [24];
the observed accumulation of PR
pse H69E mature pro-
tease in the cell lysate was consistent with a reduced
proteolytic activity. Nevertheless, the PR
pse H69E pre-
cursor generated similar amounts of processing pro-
ducts as the wild type controls, suggesting that PR
pse
H69E is competent for autoprocessing of the GST
fusion precursor even though it possesses reduced
activity. The PR
NL H69D mutant also demonstrated a
phenotype very similar to PR
pse H69E. These results
appeared different from a previous report indicating
that in VLPs produced by PR
pse H69E and PR
NL H69D
proviruses, the full-length protease precursor is the
predominant polypeptide and processed intermediates
are undetectable[14,24]. We speculate this discrepancy
to indicate that a suppressing mechanism exists to pre-
vent Gag-Pol precursor autoprocessing in the context
of the provirus, which is missing in the GST fusion
precursor system. In the context of the provirus, a
combination of reduced catalytic activity and a viable
suppressing mechanism could completely abolish PR
pse
H69E and PR
NL H69D autoprocessing. In the absence
of the suppressing mechanism, as in the GST fusion
precursors reported herein, the proteases with reduced
activities were still able to autoprocess releasing
mature protease. Further investigation is essential to
define the suppressing mechanism.
Cleavage preference between the two authentic clea-
vage sites was also observed in this report. The proxi-
mal cleavage site was preferentially processed by the
PR
pse precursor whereas the PR
NL precursor cleaved
the distal site more frequently. A simple interpretation
would be that the two proteases have different sub-
strate preferences because amino acid sequences at the
cleavage sites are identical in the two precursors.
A previous study demonstrated that both sites are
cleaved at similar rates by mature protease when
added in trans to the HIV-1 Gag-PR
D25A-Pol precursor
in an in vitro assay [13]. At low concentrations (~ 0.2
nM), the HIV-1 Gag-Pol precursor preferentially pro-
cessed the distal site [6]. Therefore, the result of our
PR
NL precursor is consistent with the previous reports
further validating it as a model system for HIV autop-
rocessing studies. The PR
pse precursor might fold into
a structure different from the PR
NL precursor due to
different protease sequences (six substitutions [14]),
resulting in different substrate exposure. Alteration of
H69 to other amino acids (Q and E) in the PR
pse back-
bone changed cleavage preference, also supporting the
latter idea. Nevertheless, detailed structural analysis of
these precursors will be required to determine the
mechanism of cleavage preference.
The role of the TFR in protease autoprocessing has
been difficult to assess because the coding sequence
overlaps with the frameshifting signal and the p6 cod-
ing sequence. Using our GST fusion system, we
demonstrated that the TFR is not required for the
proximal cleavage event that releases mature protease.
Additionally, replacement of the TFR with another
unrelated peptide (N-Hec1) did not impact autopro-
cessing. This result is consistent with a recent report
by the Ralf Wagner group demonstrating that partial
substitution or deletion of 63% of the TFR did not
affect virus growth and infectivity [28]. Collectively,
these data suggest that TFR mainly serves as a linker
between the frameshift site and the mature protease.
Consistent with this role, the TFR polypeptide has not
been shown to have a defined structure by itself.
However, it remains to be determined whether TFR
regulates protease structures in an auxiliary manner
during autoprocessing in the infected cell. In line with
this, about two decades ago Partin et al reported that
TFR deletion enhances the proteolytic processing of
an HIV-1 protease precursor generated by in vitro
transcription/translation [29]. Therefore, more investi-
gation will be necessary to further define TFR
function.
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DNA mutagenesis
Plasmids used in this study were generated following
standard molecular cloning procedures. Construction of
pGEX-3X-derived plasmids expressing GST-TFR-PR
pse-
Flag and GST-TFR-PR




were described previously [24]. All plasmids for mam-
malian expression of GST-fused miniprecursors were
derived from the pEBG parental vector in which expres-
sion of GST is driven by the human EF-1a promoter
[30]. The TFR sequence was derived from NL4-3 and
the protease sequences were either from NL4-3 or a
previously described pseudo wild-type protease [24]. In
order to facilitate detection of the full length precursor
and its derivatives, sequence encoding a Flag tag was
inserted between the GST and TFR coding sequences
and sequence encoding a HA tag was added to the C-
terminus of the PR coding sequence. Mutations were
introduced into the GST-Flag-TFR-PR-HA backbone by
PCR-mediated site-directed mutagenesis. Template plas-
mid encoding the N-terminus of Hec1 (Highly expressed
in cancer) [31] was kindly provided by Dr. Jennifer
Deluca (Colorado State University) for PCR amplifica-
tion of the insert. All the plasmids were verified by
DNA sequencing and the sequence information is avail-
able upon request.
Bacterial expression of GST fused miniprecursors
The pGEX-3X-derived plasmids were transformed into
E. coli BL21 (Novagen, San Diego, CA), and transformed
colonies were individually grown in Luria-Bertani med-
i u ma t3 7 ° Co v e r n i g h t .T h eo v e r n i g h tc u l t u r ew a st h e n
d i l u t e d1 0 0 - f o l di n t o2 × Y Tm e d i u m( 1 0g / Ly e a s t
extract, 16 g/L tryptone, 5 g/L NaCl) and incubated at
37°C for 2.5~3 h prior to the addition of isopropyl thio-
galactoside (IPTG; 40 μM) to induce protein expression.
Following addition of IPTG, cells were incubated for 4 h
at 30°C and then cells were collected by centrifugation.
For western blot analysis, cell pellets derived from equal
volumes of culture medium were directly lysed in SDS/
PAGE loading buffer.
Cell culture, transfection and western blotting
Human embryonic kidney-derived 293T cells were
maintained in DMEM (Dulbecco’s Modified Eagle’s
Medium; Invitrogen, Carlsbad, CA) as previously
described [24,32]. For in vitro transfection, 293T cells
were plated in 6-well plates and incubated overnight to
achieve 50-60% confluence at the time of transfection.
One hour prior to transfection, chloroquine was added
to each well to a final concentration of 25 μM. A total
of 1 μg DNA in 131.4 μLo fd d H 2Ow a sm i x e dw i t h
18.6 μl2MC a C l 2 to give a final volume of 150 μl.
Then, 150 μlo fH B S( 5 0m MH E P E S ,2 8 0m MN a C l ,
10 mM KCl, 12 mM Dextrose, 1.5 mM Na2HPO4,p H
7.05) was added drop-wise to the DNA solution. The
resulting mixture was directly added to the 293T cells.
After 7-11 h of incubation, the culture medium was
replaced with chloroquine-free DMEM.
To examine proteins in transfected cells, post-nuclear
cell lysates were prepared as described previously
[24,32]. In brief, transfected cells from each well of a 6-
well plate were lysed in situ using 200 μL lysis buffer
(25 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% sodium
deoxycholate, 1% Triton X-100, and protease inhibitor
cocktail). The lysate was then centrifuged at 20800× g
for 2 min to remove the nuclei and 20 μLo ft h er e s u l t -
ing supernatant was subjected to SDS-PAGE followed
by western blot analysis using polyvinylidene fluoride
membrane. Unless indicated otherwise, cell lysates were
prepared 40-48 h post transfection. To examine proteins
associated with released virus-like particles (VLPs), cul-
ture medium was collected 11-48 h post transfection
and centrifuged at 20,800 × g for 2 min at ambient tem-
perature. The clarified supernatant was then collected
and centrifuged at 20,800 × g for 3 h at 4°C to pellet vir-
ions. Virion pellets were resuspended in 30 μL PBS and
15 μL aliquots were subjected to SDS-PAGE analysis.
Mouse anti-HIV p24 (Cat# 3537) and rabbit anti-HIV-
1 protease serum (Cat# 4105) were obtained from the
NIH AIDS research and reference program. Purchased
primary antibodies included mouse anti-HA, anti-FLAG,
(Sigma, St. Louis, MO) and mouse anti-GAPDH (Gly-
ceraldehyde-3-phosphate dehydrogenase; clone 6C5,
Fisher Scientific, Pittsburgh, PA). Polyclonal rabbit anti-
GST, a kind gift from Dr. Santiago Di Pietro (Colorado
State University), was raised against purified GST-Rab38
and GST-Rab32 proteins and purified through GST col-
umn. Infrared dye-labeled secondary antibodies were
obtained from Rockland Immunochemicals, Inc. (Gil-
bertsville, PA). Western blot images were captured
using an Odyssey infrared dual laser scanning unit (LI-
COR Biotechnology, Lincoln, Nebraska).
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